8-K: Bausch Health to Acquire DURECT Corporation, Bolstering Liver Disease Pipeline

Bausch Health Companies Inc. announced a definitive agreement to acquire DURECT Corporation, gaining larsucosterol, a novel therapeutic with FDA Breakthrough Therapy Designation for alcoholic hepatitis.

Summary

• Bausch Health (BHC) will acquire DURECT Corporation (DURECT) through a tender offer by its wholly-owned subsidiary, BHC Lyon Merger Sub, Inc.
• The acquisition includes DURECT's lead asset, larsucosterol, an epigenetic modulator with FDA Breakthrough Therapy Designation for alcoholic hepatitis (AH).
• The offer is $1.75 per share in cash, plus one non-transferrable contingent value right (CVR) for each share, representing a pro rata portion of up to $350 million in aggregate milestone payments based on net sales.
• The upfront cash consideration is approximately $63 million.
• The upfront purchase price represents a premium of approximately 191% to DURECT's 30-day volume-weighted average trading price and 217% to its trading price on July 28, 2025.
• Larsucosterol has shown promising Phase 2 results for AH, a life-threatening form of alcohol-associated liver disease with no currently FDA or EMA approved treatment.
• A registrational Phase 3 program for larsucosterol in severe AH is being planned, with 90-day survival as the primary endpoint.
• The acquisition complements Bausch Health's ongoing RED-C clinical program for rifaximin SSD in cirrhotic patients, with Phase 3 results expected in early 2026.

Sentiment

Score: 8

Explanation: The acquisition of a breakthrough therapy designated asset addressing a significant unmet medical need is a strong strategic positive for Bausch Health, enhancing its pipeline and market position in hepatology. The high premium paid for DURECT reflects the perceived value of larsucosterol.

Positives

• Acquisition of larsucosterol, a novel therapeutic with FDA Breakthrough Therapy Designation for alcoholic hepatitis (AH).
• Larsucosterol has the potential to be the first FDA-approved therapeutic option for AH, addressing a significant unmet medical need.
• Strengthens Bausch Health's commitment and existing expertise in hepatology and liver disease.
• Complements Bausch Health's ongoing Phase 3 program for rifaximin SSD.
• The transaction provides significant immediate and long-term value for DURECT stakeholders.

Negatives

• The contingent value rights (CVRs) introduce variability in the total acquisition value for DURECT shareholders, dependent on future sales milestones.
• Larsucosterol is still in clinical development (planning Phase 3), meaning its approval and commercial success are not guaranteed.

Risks

• Uncertainties relating to the timing of the consummation of the proposed transaction.
• Possibility that any or all conditions to the consummation of the transaction may not be satisfied or waived.
• Failure to obtain requisite stockholder approval of DURECT.
• Effect of the announcement or pendency of the transaction on the parties' ability to maintain relationships with customers, suppliers, and other business partners.
• Impact of the transaction, if consummated, on Bausch Health's business, financial position, and results of operations, including expectations regarding margin expansion, accretion, and deleveraging.
• Risks relating to potential diversion of management attention away from the parties' ongoing business operations.
• No assurance that the conditions to closing the transaction will be satisfied or that the tender offer and the transaction will be consummated.

Future Outlook

Bausch Health plans a registrational Phase 3 program for larsucosterol to evaluate its safety and efficacy for severe alcoholic hepatitis, with 90-day survival as the primary endpoint. Efficacy and safety results for Bausch Health's rifaximin SSD Phase 3 program are expected in early 2026. The acquisition is expected to close in the third quarter of 2025.

Management Comments

• "This announcement is fundamental progress on our Strategic Priority—Innovation, which is to intensify focus and operating rigor behind R&D and business development and demonstrates our commitment to hepatology and finding new ways to address unmet medical needs, living our purpose of enriching lives through our relentless drive to deliver better health outcomes for patients." Thomas J. Appio, CEO, Bausch Health.
• "There is a significant unmet need in the treatment of patients with AH given the high mortality rate and that there are no currently approved treatments. We are very excited to add larsucosterol, an asset which has FDA Breakthrough Therapy Designation, to our pipeline, particularly as it builds on our existing expertise within the hepatology space. It is complementary to our ongoing Phase 3 program of soluble solid dispersion of rifaximin (rifaximin SSD) being studied in cirrhotic patients globally." Jonathan Sadeh M.D., M.Sc., EVP, Chief Medical Officer and Head of R&D, Bausch Health.
• "AH, by our estimates, is responsible for about 100 deaths per day in the US and billions of dollars in healthcare costs. Since we reported results from our Phase 2b AHFIRM clinical trial for larsucosterol in AH, our primary focus has been advancing larsucosterol towards the completion of clinical development. We chose this transaction with Bausch Health because we believe it provides significant value for our stakeholders, both immediately and in the long term, should larsucosterol be approved and achieve commercial success. We view Bausch Health as the right partner to advance larsucosterol due to their expertise in hepatology, commercial success with Xifaxan and experienced development team." James E. Brown, D.V.M., President and CEO, DURECT.
• "The addition of larsucosterol to our pipeline is a strategic fit with our focus in hepatology and underscores our continued dedication to exploring and identifying new treatments for individuals who are suffering with liver disease and its complications. We are excited to continue investment in bringing these breakthrough options to market, not just in the US, but also globally." Aimee Lenar, Executive Vice President of US Pharma, Bausch Health.

Industry Context

The acquisition positions Bausch Health to address a critical unmet medical need in alcoholic hepatitis, a severe liver disease with no currently approved treatments. This move aligns with a broader industry trend of pharmaceutical companies seeking to acquire innovative assets, especially those with FDA Breakthrough Therapy designations, to expand specialized pipelines and target high-mortality conditions. Bausch Health leverages its existing expertise and commercial success in hepatology (e.g., with Xifaxan) to integrate larsucosterol, aiming to become a leader in liver disease solutions.

Comparison to Industry Standards

• There are currently no FDA or EMA approved treatments for alcoholic hepatitis, making larsucosterol a potential first-in-class therapeutic option if approved.
• Bausch Health's existing product, Xifaxan, is cited as an example of their commercial success in hepatology, indicating their capability to commercialize new liver disease treatments.
• The acquisition of a drug with FDA Breakthrough Therapy Designation is a common strategy for pharmaceutical companies to accelerate development and potentially gain market exclusivity in areas of high unmet need, similar to other companies pursuing fast-track pathways for novel therapies.

Stakeholder Impact

• Shareholders (Bausch Health): Potential for long-term value creation through pipeline expansion and entry into a high-need market, but also immediate dilution from the acquisition cost and integration risks.
• Shareholders (DURECT): Immediate significant premium on their shares ($1.75 per share cash) and potential for additional value through contingent value rights (up to $350 million aggregate) if larsucosterol achieves sales milestones.
• Patients with Alcoholic Hepatitis: Potential for a first FDA-approved therapeutic option, offering hope for a life-threatening condition with high mortality.
• Employees (DURECT): Retention bonuses mentioned in relation to milestone payments, indicating efforts to retain key personnel.
• Medical Community: Introduction of a novel therapeutic strategy for a challenging disease, potentially improving patient survival and treatment paradigms.

Next Steps

• BHC Lyon Merger Sub, Inc. will commence a tender offer to purchase all outstanding shares of DURECT common stock.
• If the tender offer is successful, it will be followed by a merger of BHC Lyon with and into DURECT.
• Bausch Health is planning a registrational Phase 3 program to evaluate the safety and efficacy of larsucosterol for the treatment of patients with severe alcoholic hepatitis.
• Efficacy and safety results for Bausch Health's RED-C clinical program (rifaximin SSD) are expected to be announced in early 2026.

Key Dates

Recommendation

The acquisition of DURECT and its lead asset, larsucosterol, represents a significant strategic move for Bausch Health, positioning it strongly in the hepatology market with a potential first-in-class treatment for alcoholic hepatitis, a condition with high unmet medical need and no approved therapies. The FDA Breakthrough Therapy Designation for larsucosterol de-risks its development pathway to some extent and signals regulatory confidence. While clinical development risks remain, Bausch Health's existing expertise and commercial infrastructure in hepatology (e.g., Xifaxan) make it a suitable partner to advance larsucosterol. The high premium paid for DURECT reflects the perceived value of this asset. This acquisition enhances Bausch Health's long-term growth prospects and pipeline, making it an attractive investment for those seeking exposure to innovative pharmaceutical assets addressing critical medical needs.

Keywords

Bausch Health, DURECT Corporation, acquisition, merger, larsucosterol, alcoholic hepatitis, AH, liver disease, hepatology, FDA Breakthrough Therapy, tender offer, pharmaceutical, drug development, clinical trials, epigenetic modulator, rifaximin SSD